RxDoctor Payments Data

Jordan Hamric, OD

Optometrist · Morgantown, WVNPI 1770010738

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,761 of the $5,909 with a category attached, or 80.6%. 17 manufacturers reported payments, led by Coopervision Inc. at 30.8% of the total. Among optometrist clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,909in general payments, 2019–2025

Across 148 payments — averaging $39.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$2K
  • Bausch & Lomb Americas Inc.$1K
  • Johnson & Johnson Vision Care, Inc.$940
  • Alcon$390
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$380
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$292
  • plus $955 from 11 others
$13,660in research payments, 2019–2025

Across 5 payments — averaging $2732.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coopervision Inc.$14K

What the payments were for

  • Consulting fees$1,14819%
  • Food & beverage$4,76181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,909 in reported general payments places this provider in the 90th percentile of 210 optometrist providers in West Virginia.

See all optometrist providers in West Virginia

Medicare billing

Part B allowed, 2024
$10,253
Medicare patients
70
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast13$9,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$1,136$9,38713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 optometrist providers in West Virginia.

Other optometrist in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →